Orion planning new packaging and logistics centre - new jobs in Salo
Due to increased production volumes, Orion is planning to centralise some of its pharmaceutical packaging and logistics functions in Salo in premises to be acquired from Nokia. According to a letter of intent signed by the companies, Orion would acquire production and storage space and establish a new packaging and logistics centre in these premises.
Adapting the premises to Orion's needs would start at the beginning of next year, and operations in the new premises would start approximately during 2013. The packaging and logistics centre would be functioning at full capacity in the autumn of 2014. If completed, the project would increase the number of Orion's personnel in Finland, and when ready, the centre would provide jobs approximately for over 100 people.
Orion has today started negotiations with personnel representatives regarding reorganisation of work. It is anticipated that in addition to the need to increase the number of personnel, it will be possible to provide each employee involved in the negotiations with a job in Salo, or at Orion's other business locations in Espoo and Turku, as a result of growing production volumes and personnel planning.
"The new packaging and logistics centre would enable us to expand and intensify our operations; as our current packaging premises in Espoo and Turku are not big enough to enable this. The availability of new personnel in the Salo area is also a significant factor when we are considering solutions for the development of our packaging and logistics functions," says Senior Vice President Virve Laitinen, Supply Chain, Orion.
Virve Laitinen, Senior Vice President, Supply Chain, Orion Corporation
Tel. +358 50 966 4373
Tel. 07180 34900
Orion Corporation Communications
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the Company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
Orion's production plants are all located in Finland: in Espoo, Turku, Oulu, Hanko and Kuopio.